Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis. Experimental Design: Dose levels (DL) were dasatinib 50 mg twice daily (DL1), 70 mg twice daily (DL2 and DL3), or 100 mg daily (DL3a); plus capecitabine on days 1 to 14 of a 21-day cycle, at 825 mg/m2 twice daily (DL1 and DL2) or 1,000 mg/m2 twice daily [DL3 and DL3a (MTD)]. DL3a was expanded to evaluate safety/efficacy. Plasma samples were collected for biomarker analysis. Results: Thirty-one and 21 patients were treated in the escalation and expansion phases. Sixty percent of tumors were hormone receptor–positive. Most common adverse events (AE) were any grade nausea (58%), hand–foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%). Most common grade 3/4 AEs were hand–foot syndrome (12%), diarrhea (8%), fatigue (8%), pleural effusion (8%), and vomiting (6%). The MTD was defined at DL3a (capecitabine 1,000 mg/m2 twice daily and dasatinib 100 mg daily). Of 25 response-evaluable patients treated at DL3a, confirmed partial response was noted in 24% and stable disease in an additional 32%; median progression-free survival was 14.4 weeks. Significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV were observed. Conclusions: Dasatinib 100 mg once daily plus capecitabine 1,000 mg/m2 twice daily were tolerable and were associated with clinical benefit in 56% of response-evaluable patients. Biomarker changes were consistent with an antiangiogenic effect. Clin Cancer Res; 19(7); 1884–93. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Cited by
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“I capecitabine PR = 24% SD = 32% 50 or 70 mg twice or 100 mg daily 2013 [111]”
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer
Elsberger, B. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.009 · Cited by 54
Metadata
- Authors
- Somlo, G., Atzori, F., Strauss, L. C., Geese, W. J., Specht, J. M., Gradishar, W. J., Rybicki, A., Sy, O., Vahdat, L. T., & Cortes, J.
- Venue
- Clinical Cancer Research
- Published
- 2013-04-01
- Volume
- 19
- Issue
- 7
- Pages
- 1884-1893
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2038147464
- Cited by
- 53
- References
- 3
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0652
- The paper
- Somlo, G., Atzori, F., Strauss, L. C., Geese, W. J., Specht, J. M., Gradishar, W. J., Rybicki, A., Sy, O., Vahdat, L. T., & Cortes, J. (2013). Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0652
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.